Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

56.29USD
26 Jul 2016
Change (% chg)

$0.99 (+1.79%)
Prev Close
$55.30
Open
$56.37
Day's High
$56.46
Day's Low
$56.04
Volume
979,222
Avg. Vol
1,265,613
52-wk High
$60.34
52-wk Low
$46.17

Select another date:

Mon, Jul 4 2016

Novo Nordisk invests $60 mln to expand insulin plant in Kalundborg

* Danish pharmaceutical company Novo Nordisk is investing 400 million Danish crowns ($59.70 million) in a 500 square meter extension of the world's largest insulin production plant in Kalundborg, it said on Monday.

BRIEF-Ypsomed Holding collaborates with Novo Nordisk

* Collaborates with Novo Nordisk to provide new solutions in insulin pump therapy Source text: http://bit.ly/293IVRQ Further company coverage: (Gdynia Newsroom)

BRIEF-Novo A/S, main owner of Novo Nordisk, appoints Kasim Kutay as new CEO

* Says appoints Kasim Kutay as new CEO from September 1, 2016

Novo diabetes drug cuts heart risks by less-than-hoped 13 percentage

Novo Nordisk's top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a closely watched study, but the result disappointed investors who had hoped for more.

UPDATE 2-Novo diabetes drug cuts heart risks by less-than-hoped 13 pct

* Investors had hoped for bigger benefit, shares off 5 pct (Adds further reaction, latest shares)

BRIEF-Novo Nordisk reports positive results from semaglutide trial

* Says semaglutide demonstrated superior improvements in glycaemic control vs rivals sitagliptin and exenatide ER in two clinical trials in adults with type 2 diabetes

U.S. panel backs approval of Sanofi combination diabetes drug

One day after recommending approval of a new diabetes drug made by Novo Nordisk A/S, a U.S. advisory panel on Wednesday recommended approval of a similar product made by Sanofi SA.

UPDATE 2-U.S. panel backs approval of Sanofi combination diabetes drug

May 25 One day after recommending approval of a new diabetes drug made by Novo Nordisk A/S, a U.S. advisory panel on Wednesday recommended approval of a similar product made by Sanofi SA.

European shares hit new 4-week high, Novo Nordisk leads

LONDON, May 25 European shares climbed to a new four-week high on Wednesday, with Novo Nordisk leading the market higher after a U.S. advisory panel recommended approval of its new diabetes drug, while higher copper prices lifted miners.

FDA panel recommends approval of Novo Nordisk diabetes drug

A U.S. advisory panel on Tuesday recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combination designed to be both effective and convenient.

Select another date: